Clinical and Translational Mycology on the southern shores: perspective from the Australia and New Zealand Mycoses Interest Group
Monica A Slavin A B D and Sharon C-A Chen C
+ Author Affiliations
- Author Affiliations
A Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia
B The Doherty Institute for Infection and Immunity, Parkville, Vic., Australia
C Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR – Pathology West, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
D Tel: +61 3 9656 1599, Fax: +61 3 9656 1185, Email: Monica.Slavin@petermac.org
Microbiology Australia 36(2) 57-59 https://doi.org/10.1071/MA15020
Published: 25 March 2015
Abstract
The hosting of the 19th International Society of Human and Animal Mycology (ISHAM) Congress, the premier international forum for medical, veterinary and basic science mycology, in Melbourne, Australia in 2015, has prompted the opportunity to journey through the beginnings and rationale of coordinated and systematic study of clinical and applied mycology in Australia. The Australia and New Zealand Mycoses Interest Group (ANZMIG) is a special interest group of the Australasian Society for Infectious Diseases (ASID). This year, it has the honour of hosting, and the scientific organisation of, the 19th ISHAM Congress, which includes symposia sessions co-badged with the Mycoses Study Group, USA and the International Immunocompromised Host Society. Australian speakers make a strong contribution to the program in Clinical, Translational, Basic Science and One Health streams.
References
[1] Chen, S. et al. (2006) Active surveillance for candidemia, Australia. Emerg. Infect. Dis. 12, 1508–1516.| Active surveillance for candidemia, Australia.Crossref | GoogleScholarGoogle Scholar | 17176564PubMed |
[2] van Hal, S.J. et al. (2014) Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study. J. Antimicrob. Chemother. 69, 2210–2214.
| Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXht1SqsbnP&md5=a3b248fb5e13f7381796aa6bd276d7c2CAS | 24788656PubMed |
[3] Heath, C.H. et al. (2009) Population-based surveillance for scedosporiosis in Australia: clinical epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin. Microbiol. Infect. 15, 689–693.
| Population-based surveillance for scedosporiosis in Australia: clinical epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD1MrltVCmtA%3D%3D&md5=33b4a3bd90077c33859d1db8d2064dc2CAS | 19549223PubMed |
[4] Slavin, M. et al. (2015) Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clin. Microbiol. Infect. , .
| Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality.Crossref | GoogleScholarGoogle Scholar | 25677259PubMed |
[5] Chen, S.C. et al. (2012) Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin. Infect. Dis. 55, 789–798.
| Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death.Crossref | GoogleScholarGoogle Scholar | 22670042PubMed |
[6] Morrissey, C.O. et al. (2013) Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect. Dis. 13, 519–528.
| Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXntVaktb0%3D&md5=e7ca435ccc07a7120e68ac32d52387efCAS | 23639612PubMed |
[7] Head, M.G. et al. (2014) Systematic analysis of funding awarded for mycology research to institutions in the UK, 1997–2010. BMJ Open. 4, e004129.
| Systematic analysis of funding awarded for mycology research to institutions in the UK, 1997–2010.Crossref | GoogleScholarGoogle Scholar | 24413353PubMed |
[8] Slavin, M.A. (2008) Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting. Intern. Med. J. 38, 457–467.
| 1:STN:280:DC%2BD1cvos1ejtw%3D%3D&md5=b9371e0f29eb56d511151562d4f38396CAS | 18588519PubMed |
[9] Agrawal, S. et al. (2012) A practical critique of antifungal treatment guidelines for haematooncologists. Crit. Rev. Microbiol. 38, 203–216.
| A practical critique of antifungal treatment guidelines for haematooncologists.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38Xpsl2itLc%3D&md5=1fb617d50a511f244c14a580e24693ecCAS | 22324737PubMed |
[10] van Hal, S.J. et al. (2014) A survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand. Intern. Med. J. 44, 1277–1282.
| A survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC2Mzmt12rtw%3D%3D&md5=e33b951806050c275ea696ee59258c7eCAS | 25482740PubMed |
[11] Fleming, S. et al. (2014) Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern. Med. J. 44, 1283–1297.
| 1:STN:280:DC%2BC2Mzmt12rtA%3D%3D&md5=e5d580220bca4b7a68ed746d62ac9c90CAS | 25482741PubMed |
[12] Morrissey, C.O. et al. (2014) Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014. Intern. Med. J. 44, 1298–1314.
| Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC2Mzmt12rtQ%3D%3D&md5=f1b674624b1cd7da986dd2fedd9b70d0CAS | 25482742PubMed |
[13] Chen, S.C. et al. (2014) Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern. Med. J. 44, 1315–1332.
| Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC2Mzmt12rug%3D%3D&md5=53018326fed101654cc1735ce5501564CAS | 25482743PubMed |
[14] Blyth, C.C. et al. (2014) Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern. Med. J. 44, 1333–1349.
| Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC2Mzmt12ruw%3D%3D&md5=2984603eaf5034e99f58d50c637d8511CAS | 25482744PubMed |
[15] Cooley, L. et al. (2014) Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern. Med. J. 44, 1350–1363.
| Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC2Mzmt12qsg%3D%3D&md5=8726716f257800f487224c8888f44f5aCAS | 25482745PubMed |
[16] Chau, M.M. et al. (2014) Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern. Med. J. 44, 1364–1388.
| Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXitVers7jJ&md5=451861127258d884ef03cba1d7047943CAS | 25482746PubMed |
[17] Chang, C.C. et al. (2014) Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014. Intern. Med. J. 44, 1389–1397.
| Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC2Mzmt12qsA%3D%3D&md5=baf8aafd7e0e97fe336c0a06d9ca261aCAS | 25482747PubMed |
